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OBJECTIVES: There is some concern that thiazolidinediones
(TZDs) may be associated with an increased risk of heart failure.
This study compares risk of heart failure in patients initiated on
TZDs or metformin in a Medicaid Managed Care Organization
(MCO). METHODS: Retrospective cohort study using pre-
scription and medical claims of Medicaid MCO patients. The
study included new users of either metformin or TZDs, 18 years
or older with a ﬁrst prescription between June 15, 2000 and June
15, 2002. We built logistic regression models to assess likelihood
of developing heart failure after TZD or metformin use, adjust-
ing for age, gender, race, urban/non-urban setting, and history
of comorbidities including heart failure, diabetes, hypertension,
hyperlipidemia, liver disease, and kidney disease. Risk of devel-
oping heart failure in patients initiated on TZDs was also com-
pared to a propensity-matched sample of those initiated on
metformin using multivariate logistic regression with stratiﬁca-
tion on matched pairs. RESULTS: Of 3397 patients in the study,
those receiving TZDs (N = 905) were older (mean age 49) than
those receiving metformin (N = 1755, mean age 46). Patients
older than 60 (OR = 1.4, 95%CI: 1.1–1.8, P = 0.0123), Cau-
casian (OR = 1.3, 95%CI: 1.1–1.6, P = 0.0039) or residing in
non-urban areas (OR = 1.4, 95%CI: 1.2–1.6, P < 0.0001 ), were
more likely to be started on TZDs. Logistic regression results
show older age (OR = 2.5, 95%CI: 1.4 to 4.4, P < 0.001) and
history of hyperlipidemia (OR = 0.7, 95%CI: 0.5 to 1.4, P =
0.0269) were signiﬁcant predictors of heart failure. Initiation on
TZDs or metformin is not a signiﬁcant predictor of heart failure
(OR = 1.3, 95%CI: 0.9 to 1.8, P = 0.0642). Results from the
propensity adjusted model were consistent, showing no signiﬁ-
cant association between initiation on TZDs or metformin and
heart failure (OR = 1.2, 95%CI: 0.9–1.5, P = 0.3381). CON-
CLUSIONS: In this Medicaid MCO population, there is no




PRESCRIPTION DRUG COST-SHARING AND
ANTICOAGULANT DRUG USE—UNINTENDED EFFECTS OF
THINNER BENEFITS
Hsu J1, Huang J1, Price M1, Brand R2, Fung V1, Fireman B1, Hui R1,
Newhouse JP3, Selby JV1
1Kaiser Permanente, Oakland, CA, USA; 2University of California at
San Francisco, San Francisco, CA, USA; 3Havard University, Boston,
MA, USA
OBJECTIVES: We investigated the impact of a prescription drug
plan with a $1000 annual beneﬁt cap on drug consumption,
adherence, and clinical events. METHODS: All subjects were
65+ years with Medicare insurance, had tiered copayments ($10
for generic & $20–35 for brand drugs), received an anticoagu-
lant drug in 2002, and were members of an integrated, prepaid
delivery system. We used linear and logistic regression models to
examine the association between having a cap and drug con-
sumption in 2003 (in dollars), and between having a cap and
drug adherence (“adherent” if proportion of days covered °Y¢
0.8). We used Poisson and negative binomial regression models
to examine the association between having a cap and unfavor-
able clinical event rates (i.e. emergency department (ED) visits
and non-elective hospitalizations). We adjusted for age, gender,
race/ethnicity, socioeconomic status, comorbidity (DxCG
scores), and medical center. RESULTS: The 17,615 subjects had
a mean age of 76.7 years (SD = 6.8) and 51.1% were female. In
2003, 77.4% of subjects had a $1000 annual drug beneﬁt cap,
and the remaining subjects had no beneﬁt limit. In the multi-
variate model, subjects with a cap consumed 28.4% less of all
drugs and 21.7% less of anticoagulant drugs than their expected
overall drug consumption if they had no cap (consumption in
dollars, p-value <0.0001). Anticoagulant drug adherence was
lower in cap versus non-cap subjects, e.g. OR = 0.74 (95% CI:
0.68–0.79). Finally, compared to non-cap subjects, cap subjects
had increases in ED visit and non-elective hospitalization rates
for any reason: RR = 1.16 (95% CI: 1.04 ¨C 1.30) and RR =
1.14 (95% CI: 1.01 ¨C 1.30), respectively. CONCLUSIONS: In
patients age 65+, with Medicare insurance, and who received
anticoagulant therapy, these preliminary results suggest that pre-
scription drug beneﬁt caps were associated with less drug con-
sumption, lower treatment adherence, and higher unfavorable
clinical event rates.
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OBJECTIVE: Employer Pitney Bowes lowered plan participant
co-payments for oral diabetic medications, insulin and long-term
asthma controllers on January 1, 2002 to promote participant
adherence and potential medical cost savings. METHODS: A
longitudinal retrospective analysis of pharmacy claims data was
conducted to evaluate changes in plan participant adherence
before and two years after the beneﬁt change. Adherence was
measured using the Adherence Index (AI), a published method
based on medical-cost regression modeling of plan participant-
level persistency and compliance with therapy as measured from
pharmacy claims history. Full-time employees and dependents
with diabetes and asthma were identiﬁed using medical and
pharmacy claims algorithms. Pharmacy eligibility was required
between January 1, 2001 and December 31, 2003. RESULTS:
Potential users identiﬁed included 318 asthmatics (average age
28.6 years) and 297 diabetics (average age 48.28 years). Mean
adherence signiﬁcantly increased in the year after the beneﬁt
change for long-term asthma controller users (n = 94) (baseline
mean 0.76 (standard deviation (s.d.) = 0.19); follow-up year one
mean 0.82 (s.d. = 0.14) paired samples t-test p < 0.0001). Long-
term asthma controller adherence in follow-up year two
remained signiﬁcantly higher than baseline but was not signiﬁ-
cantly different from follow-up year one. There was a signiﬁcant
shift in the percentage of asthmatic plan participants with sub-
optimal adherence (AI < 0.80) from 20 percent to 5 percent
(McNemar p value = 0.003). A signiﬁcant increase in follow-up
year one adherence was also detected for insulin users in (n =
46): (baseline mean 0.78 (standard deviation (s.d.) = 0.15);
follow-up year one mean 0.84 (s.d. = 0.12) paired samples t-test
p < 0.0001). Adherence increases were not measured in the oral
diabetic category which had higher baseline adherence (Mean =
0.94, (s.d. = 0.11). CONCLUSION: This analysis suggests there
may be an association between a reduction in co-pay and plan
participant adherence as measured in claims data.
